GlassScriptPhysician profile
Thomas W Biggs
NPI 1932188224
$4,558.00
in general payments reported to CMS, 2019-2025
31 companies · $908 in 2025
The $908 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $284 · 2021: $386 · 2022: $947 · 2023: $895 · 2024: $679 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,401.48 | 2019-2025 | Hydrus Microstent, Clareon, Unity |
| Musculoskeletal Transplant Foundation INC. | $246.07 | 2023-2024 | |
| Carl Zeiss Meditec USA, INC. | $208.94 | 2022-2025 | |
| Rxsight INC | $201.46 | 2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Ocular Therapeutix, INC. | $187.99 | 2022 | |
| Sight Sciences, INC. | $149.94 | 2024 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $135.16 | 2019-2025 | |
| Glaukos Corporation | $108.07 | 2019-2025 | Idosetr |
| Regeneron Healthcare Solutions, INC. | $102.61 | 2023-2024 | Dupixent |
| Tarsus Pharmaceuticals, INC. | $91.31 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.16 | 2019-2020 | |
| Biotissue Holdings INC. | $75.03 | 2021-2025 | |
| Allergan, INC. | $65.76 | 2019-2022 | |
| Abbvie INC. | $60.58 | 2022-2024 | Lumigan, Alphagan P |
| Janssen Biotech, INC. | $56.82 | 2024-2025 | Stelara, Tremfya |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $46.51 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Amgen INC. | $38.63 | 2024 | Tepezza |
| Dompe US, INC. | $36.12 | 2022-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $34.74 | 2020-2021 | |
| Oyster Point Pharma, INC. | $34.55 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $31.88 | 2019-2021 | |
| Thea Pharma INC. | $21.99 | 2022 | |
| Aimmune Therapeutics, INC. | $19.69 | 2025 | Zenpep |
| Beaver-Visitec International, INC. | $18.48 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.32 | 2023 | Exparel, Zilretta |
| Johnson & Johnson Surgical Vision, INC. | $18.24 | 2021 | |
| Merck Sharp & Dohme LLC | $13.44 | 2022 | |
| New World Medical,INC. | $13.39 | 2023 | |
| Aerie Pharmaceuticals, INC. | $12.61 | 2019 | |
| Tearlab Corp | $12.50 | 2021 | |
| Shire North American Group INC | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Biggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.